NSAID use selectively increases the risk of non-fatal myocardial infarction: A systematic review of randomised trials and observational studies

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Garcí Rodríguez, Luis Alberto ^a   González Pérez, Antonio ^a,b   Bueno, Héctor ^c   Hwa, John ^d  

^a Department of Pharmacoepidemiology   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MEDLINE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; METHODOLOGY; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 79951574422     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016780     Document Type: Review

References (30)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528.
2. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
3. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo- controlled trials: the cross trial safety analysis. Circulation 117: 2104-13.
4. Grosser T, Fries S, FitzGerald GA, (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Invest J Clin 116: 4-15.
5. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR, (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359: 118-123.
6. García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A, (2004) Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109: 3000-3006.
7. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, et al. (2006) Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113: 1578-1587.
8. García Rodríguez LA, Tacconelli S, Patrignani P, (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52: 1628-1636.
9. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, et al. (2009) Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2: 155-163.
10. García Rodríguez LA, Cea Soriano L, Martín-Merino E, Johansson S, (2009) Discontinuation of Low-Dose cetylsalicylic Acid Treatment for Secondary Prevention of Cardiovascular Outcomes is Associated With an Increased Risk of Myocardial Infarction. Circulation 120: S405.
11. Curfman GD, Morrissey S, Drazen JM, (2006) Expression of concern reaffirmed. N Engl J Med 354: 1193.
12. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, et al. (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357: 360-369.
13. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, et al. (2002) Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89: 425-430.
14. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, et al. (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028-1035.
15. ADAPT Research Group (2006) Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLOS Clin Trial 1: e33.
16. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675-684.
17. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, et al. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771-1781.
18. Bennett JS, Daugherty A, Herrington D, Greenland P, Roberts H, et al. (2005) The use of nonsteroidal anti-Inflammatory drugs (NSAIDs): a science advisory from the American Heart Association. Circulation 11: 1713-6.
19. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, et al. (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 1177-84.
20. FitzGerald GA, Patrono C, (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345: 433-42.
21. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G, (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 Suppl): 234S-264S.
22. Antiplatelet Trialists' Collaboration(1994) Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106.
23. Antiplatelet Trialists' Collaboration(2002) Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. BMJ 324: 71-86.
24. Patrono C, García Rodríguez LA, Landolfi R, Baigent C, (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373-83.
25. Baigent C, Blackwell L, Collins R, Emberson J, et al. Antithrombotic Trialists' (ATT) Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-60.
26. Bueno H, Bardají A, Patrignani P, Martín-Merino E, García-Rodríguez LA, et al. (2010) Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 105: 1102-6.
27. Cannon C P, Braunwald E, (2008) - Unstable Angina and Non-ST Elevation Myocardial Infarction. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. In Libby: Braunwald's Heart Disease: A textbook of Cardiovascular Medicine, 8th Ed Philadelphia Saunders Elsevier pp. 1319-1320.
28. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA, (2006) Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98: 266-74.
29. McGettigan P, Henry D, (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633-44.
30. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302-8.